Hong Kong’s Regencell Bioscience triples in latest surge for a speculative stock

Regencell Bioscience Holdings, a bioscience company based in Hong Kong, has recently gained significant attention in the trading market despite having no revenue. The company, which focuses on developing traditional Chinese herb treatments for childhood attention deficit hyperactivity disorder (ADHD) and autism, saw its stock price surge by over 280% after a 38-for-1 split took effect on June 2. This surge led to a market capitalization of $29.7 billion by the end of the trading day, making it worth more than companies like Lululemon, eBay, and Kraft Heinz.

The momentum continued the following day, with the stock climbing an additional 30%. Regencell’s performance in 2025 has been nothing short of remarkable, with a staggering increase of 59,900% year-to-date. Despite trading for pennies at one point in the past year, the company now boasts a market value of $36 billion.

This surge in Regencell’s stock is not an isolated incident, as speculative international stocks have been attracting attention in the market. In August 2022, AMTD Digital, a Hong Kong-based fintech company, experienced a 126% increase in its stock price, briefly surpassing the market value of Coca-Cola and Bank of America.

Regencell’s decision to implement a stock split was aimed at enhancing liquidity in the market and making its shares more accessible to investors. However, stock splits do not have any impact on the fundamental aspects of a company.

The company’s focus on alternative medicines has gained traction, particularly following the appointment of Robert F. Kennedy Jr. as the Secretary of the U.S. Department of Health and Human Services. Kennedy’s stance on vaccines has raised awareness and interest in alternative treatment options.

Regencell’s core business revolves around a proprietary Traditional Chinese Medicine formula developed in collaboration with TCM practitioner Sik-Kee Au. The company’s treatment candidates for ADHD and Autism Spectrum Disorders are based on these formulas, which include natural ingredients like detoxication herbs, blood circulation herbs, and digestion herbs.

Despite the surge in its stock price, Regencell has not generated any revenue and has not applied for regulatory approvals for its TCM formulas. The company’s latest patient case studies have shown improvements in symptoms related to ADHD and ASD, but further validation and commercialization are needed.

While the stock has seen significant volatility in its trading patterns, with large one-day swings, the company’s long-term prospects remain uncertain. Retail traders have shown mixed reactions on social media platforms, with some expressing enthusiasm while others remain skeptical about Regencell’s business model and potential for growth.

In conclusion, Regencell Bioscience Holdings’ rapid rise in the trading market highlights the speculative nature of international stocks and the growing interest in alternative medicine treatments. Despite the company’s impressive stock performance, questions remain about its revenue generation, regulatory approvals, and long-term viability in the market.